Dansylarginine N-(3-ethyl-1,5-pentanediyl)amide, more commonly referred to as DAPA, is a potent (Ki=10-7M) and specific synthetic thrombin inhibitor (1). Of special interest are the unique fluorescent properties contributed by the dansyl moiety of DAPA. When bound to thrombin, the fluorescence intensity and lifetime of the dansyl moiety are increased three fold. The enhancement of fluorescence intensity, coupled with its inhibitory properties, have made this compound extremely useful for studies involving thrombin generation (2-7). In addition to an increase in fluorescence intensity and lifetime, there is a decrease in depolarization of the excitation signal which also supports fluorescence polarization studies.

The inhibitor properties of DAPA alone have been useful in a variety of applications. DAPA is routinely used as a protease inhibitor during the isolation of proteins that are susceptible to thrombin cleavage. Furthermore, by eliminating the feedback of thrombin activity during prothrombin activation, the isolation of reaction intermediates such as fragment 1.2, and meizothrombin have been made possible (7).

DAPA is synthesized according the procedure described by Nesheim, et al. (1). HPLC, TLC and spectral analyses are used to determine the purity of the final product. DAPA is supplied in water. When properly stored at -20°C and protected from light, the compound is stable for many years.

Haemtech生物制药服务（HBS）是一家领先的，符合cGMP要求的QC测试实验室，专门为生产重组和血浆衍生蛋白疗法的生物制药制造商提供分析服务，重点是那些会影响止血系统的药物。HBS使客户能够满足法规和质量测试要求，从而将其候选药物从开发转向商业化。

对生物制药的需求正在增长，并且该行业正在迅速采用外包策略，以作为满足不断升级的监管要求的一种方式。凭借在止血方面的丰富经验，HBS能够很好地协助开发影响凝血系统的药物产品。